ER-negative, PR-negative, HER2 non-amplified–ductal breast carcinoma cell line is, from a genomics perspective, one of the most intensively studied models of breast cancer as previous studies have examined its genome by whole exome mutation screening, molecular cytogenetics, massively parallel paired end sequencing and transcriptome sequencing [3], [12]–[15]. This evidence concerns the gene ERBB2 and breast carcinoma.